Our findings demonstrate that bone scintigraphy might detect favorable treatment effect of patisiran in ATTRv amyloidosis patients and possible disease progression in ATTRv amyloidosis patients treated with a TTR-stabilizer at low dose. The gene discussed is TTR; the disease is familial amyloid neuropathy.